http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-066234-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_132aa5ddba376cda52c2bedb26765245 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-567 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| filingDate | 2008-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b5c91d979e3ff5b4476e4098f33a71d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_df09c7e1b84b6de892449ce9c4bac2ae |
| publicationDate | 2009-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-066234-A1 |
| titleOfInvention | PROGESTERONE RECEIVER ANTAGONIST FOR USE IN BRCA, ONLY OR IN COMBINATION WITH AN ANTIESTROGEN |
| abstract | Individual use of the progesterone 11beta- (4-acetylphenyl) -17beta-hydroxy-17alpha- (1,1,2,2,2 -pentafluoroethyl) -estra-4,9-diene-3-one receptor antagonist, or a derivative or analogue thereof as a drug, for the prophylaxis and treatment of breast cancer mediated by BRCA1 or BRCA2, and combination comprising the progesterone receptor antagonist 11beta- (4-acetylphenyl) -17beta-hydroxy-17alpha- (1 , 1,2,2,2-pentafluoroethyl) -estra-4,9-dien-3-one, or a derivative or analogue of this pharmaceutical parauso, with at least one pure antiestrogen, for the prophylaxis and treatment of cancer Breast mediated by BRCA1 or BRCA2, ovarian cancer, endometrial cancer, gastric cancer, colorectal cancer, endometriosis, elmieloma, myoma and meningioma. Claim 2: A pharmaceutical combination according to claim 1, characterized in that the pure antiestrogen is selected from the group of compounds represented by the general formula (1), where Hal represents F or Cl, and is attached to the estratriene skeleton at position 11beta , R3 represents hydrogen, C1-4 alkyl, C1-4 alkanyl or a C3-7 cyclic ether with an O atom, R17 'represents hydrogen, C1-4 alkyl or C1-4 alkyl, R17 represents C1-4 alkyl, C1- alkyl 4, C1-4 alkynyl, and also at least partially fluorinated C1-4 alkyl radicals, where R17 '-O in the 17beta position and R17รถ in the 17alpha position are attached to the estratriene skeleton, and SK represents the UVWXYZe group, where this group it is attached to the stratriene skeleton through U at position 7alpha, where U represents a C1-13 alkylene radical, -alkenylene or -alkylene straight or branched chain, or the group AB, where A is attached to the estratriene skeleton and represents nta a benzylidene radical which is linked through -CH2- to the estratriene skeleton, a phenylene radical or a C1-3 alkylaryl radical that is linked through the alkyl group to the estrogen skeleton, and B represents a C1-13 alkylene radical, -alkenylene or straight-branched-chain alkynylene, and where A and B can also be connected to each other through another O atom, where in addition, V represents a CH2- or C (O) group, where in addition, W is an N (R6) group or an N + (O -) (R6) group, or an azolidinylene ring or an azolidinylene N-oxide ring, where the azolidinylene ring or the azolidinylene N-oxide ring includes at least a C atom in group X, where in addition, R6 is H or CH2-R7 or C (O) -R7, where R7 can have the following meaning: a) hydrogen or b) a C1-14 alkyl radical, -alkenyl or - straight or branched chain alkynyl, non-fluorinated or at least partially fluorinated, which may be hydroxylated at one or more sites, and which may be interrupted by one to three of the heteroatoms -O- and -S-, and / or the group -NR9-, where R9 represents hydrogen or a C1-3 alkyl radical, or c) an aryl to substituted unsubstituted heteroaryl radical, od) an unsubstituted or substituted C3-10 cycloalkyl radical or e) an unsubstituted or substituted C4-15 cycloalkylalkyl radical, of) an unsubstituted or substituted C7-20 aralkyl radical, or g) a substituted or substituted heteroaryl-C1-6 alkyl radical, oh) an unsubstituted or substituted aminoalkyl radical, or a biphenyl radical, where in addition, X is a C1-12 alkylene radical, -alkenylene or -alkylene straight or branched chain, where, in addition, Y is a direct bond between X and Z, or it can have the following meaning: a) a group SOn-R10, where n = 0, 1 or 2, only if W is a group N + (O -) (R6) or an N-oxide ring of azolidinylene, and not it is a group N (R6) or an azolidinylene ring, where R10 represents a direct link between SOn and Z, or a C16 alkylene radical, -alkenylene or - straight or branched chain alkynylene, or b) the group R11 or O-R11, where R11 represents i) a C1-5 alkylene radical, -alkenylene or -branched straight chain alkylene, or ii) an unsubstituted aryl radical or substituted, or a heteroaryl radical, or iii) an unsubstituted or substituted C3-10 cycloalkyl radical, or iv) an unsubstituted or substituted C4-15 cycloalkylalkyl radical, or v) an unsubstituted or substituted C7-20 aralkyl radical, or vi) a heteroaryl-C1-6-unsubstituted or substituted alkyl radical, oc) the group CH = CF od) the group HN-C (O) -NH-R12, where R12 represents an unsubstituted or substituted arylene radical, and where R12 it is attached to Z, and where in addition, Z is a direct link between Y and E, or a C1-9 alkylene radical, -alkenylene or -alkylene straight or branched chain, which may be partially or completely fluorinated, and where, in addition, E is a CF3 group or an at least partially fluorinated aryl group, and also its acid addition salts and compatible esters With the pharmacological use. |
| priorityDate | 2007-04-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.